Two Danish giants, Novo Nordisk and Novonesis, are uniting their expertise in medicine and biotechnology to explore novel approaches for enhancing human health. Their collaboration will center on the microbiome, aiming to decipher the intricate connections between microorganisms residing in and on humans and their impact on overall well-being.

The partnership seeks to leverage the strengths of both companies to develop innovative solutions. Novonesis, a producer of bacteria with demonstrated positive health effects used in various products, will contribute its knowledge of beneficial microorganisms. Novo Nordisk, with its deep understanding of human biology and focus on treating and preventing severe obesity, hopes to gain new insights into the role of gut flora in patient health.

Initial efforts will concentrate on identifying optimal combinations of existing, clinically-tested ingredients to promote metabolic health. Positive results from this preliminary research could pave the way for the development of new dietary supplements with health-promoting effects.

The collaboration aligns with Novo Nordisk’s broader ambition to address severe obesity and associated health complications through holistic and sustainable strategies. By understanding the microbiome’s role in chronic diseases, the companies aim to contribute to preventative measures and improve patient outcomes.

Both Novo Nordisk and Novonesis are committing resources, including working hours, to the joint project. The collaborative effort is structured with a steering committee and representatives from both organizations, ensuring shared costs, data, and agreements regarding potential commercial outcomes.

The partnership benefits from a shared history, as Novonesis evolved from a merger involving Novozymes, which was previously part of Novo until its spin-off in 2000. This close relationship facilitates a strong understanding and collaborative spirit between the two companies.